Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 238,014 | 164,759 | 200,589 | 126,316 | 195,442 |
| Receivables | 514,033 | 524,074 | 545,148 | 495,501 | 472,248 |
| Inventories | 160,660 | 155,526 | 134,925 | 129,765 | 127,892 |
| Other current assets | 56,030 | 76,774 | 68,911 | 56,051 | 48,807 |
| TOTAL | $1,021,325 | $972,407 | $1,010,058 | $866,182 | $897,836 |
| Non-Current Assets | |||||
| PPE Net | 1,044,128 | 1,008,047 | 1,006,330 | 907,367 | 932,877 |
| Intangibles | 1,616,405 | 1,602,876 | 1,617,191 | 1,315,499 | 1,320,076 |
| Other Non-Current Assets | 1,010,932 | 999,232 | 991,905 | 837,589 | 705,090 |
| TOTAL | $3,671,465 | $3,610,155 | $3,615,426 | $3,060,455 | $2,958,043 |
| Total Assets | $4,692,790 | $4,582,562 | $4,625,484 | $3,926,637 | $3,855,879 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 38,545 | 33,611 | 33,955 | 30,655 | 31,416 |
| Accounts payable and accrued liabilities | 111,498 | 107,231 | 99,381 | 78,523 | 66,250 |
| Accrued Expenses | 297,735 | 260,307 | 252,737 | 191,223 | 244,137 |
| Other current liabilities | 90,598 | 114,402 | 81,995 | 91,472 | 71,280 |
| TOTAL | $710,181 | $681,646 | $635,598 | $529,759 | $558,222 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,849,666 | 1,882,593 | 2,040,388 | 1,540,833 | 1,636,598 |
| Deferred Revenues | 171,805 | 166,095 | 167,530 | 137,886 | 145,139 |
| Other Non-Current Liabilities | 327,668 | 315,714 | 308,798 | 302,580 | 197,113 |
| TOTAL | $2,344,781 | $2,364,529 | $2,531,522 | $1,995,849 | $1,977,879 |
| Total Liabilities | $3,054,962 | $3,046,175 | $3,167,120 | $2,525,608 | $2,536,101 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 48,960 | 48,839 | 48,807 | 48,754 | 48,226 |
| Common Shares | 489 | 490 | 489 | 489 | 482 |
| Retained earnings | 280,329 | 213,767 | 140,957 | 97,229 | 42,096 |
| Other shareholders' equity | -174,775 | -174,490 | -162,876 | -159,700 | -170,312 |
| TOTAL | $1,637,828 | $1,536,387 | $1,458,364 | $1,401,029 | $1,319,778 |
| Total Liabilities And Equity | $4,692,790 | $4,582,562 | $4,625,484 | $3,926,637 | $3,855,879 |